IHS Chemical Week

Chemical Week Magazine :: Pharmaceuticals & Fine Chemicals

DSM Biologics to Produce Antibody for MorphoSys

10:48 AM MDT | August 25, 2008 | Deepti Ramesh

DSM Biologics, a unit of DSM, says it has signed a biopharmaceutical manufacturing agreement with biotech firm MorphoSys (Martinsried, Germany). The deal calls for DSM to develop and manufacture MOR202, a fully human antibody for the treatment of multiple myeloma, at its facility in Groningen, Netherlands. Financial terms were not disclosed. Sproll: Continuing the PER.C6 platform. DSM will use the PER.C6 technology platform of biotech firm Crucell (Leiden, Netherlands). PER.C6 has been developed for large-scale manufacturing of biopharma products including...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2012 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa